Kezar Life Sciences, Inc.
KZR · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | 0.03 | -0.00 | 10.41 |
| FCF Yield | -38.21% | -48.24% | -34.32% | -0.31% |
| EV / EBITDA | -0.59 | -0.80 | -1.20 | -286.11 |
| Quality | ||||
| ROIC | -14.06% | -15.04% | -16.20% | -14.54% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.88 | 0.93 | 1.04 | 0.83 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 25.60% | -2.15% | 3.86% | -2.82% |
| Safety | ||||
| Net Debt / EBITDA | 1.71 | 1.43 | 1.31 | 0.91 |
| Interest Coverage | -48.34 | -50.80 | -55.43 | -54.46 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -704.94 | 0.00 | -1,198.04 |